State Street Corp Avalo Therapeutics, Inc. Transaction History

State Street Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $2.01 Million - $6.99 Million	-668,851 Reduced 68.49%	307,736 $154,000
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $81,937 - $235,097	-10,824 Reduced 1.1%	976,587 $708,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $218,290 - $318,118	11,092 Added 1.14%	987,411 $1.68 Million
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $25.5 Million - $39.7 Million	976,319 New	976,319 $2.13 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $118M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.